ANIP's Quality Score rose 2 points on Tue, Nov 10, to 9. More shares traded than usual (3 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 5.1% today, while its biotech peers are down 1.4%; no story names it yet.
Fell on Nov 6
Down 3% on Nov 6 while the S&P 500 rose 0.3%.
| The company | Sales up 26% on the year |
| Latest filing | 8-K, Nov 5 |
TodayNo story names it yet.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -3.7% on average, higher 0 of 4 times.
Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
ANIP is #55 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 55 |
Expected to report Fri Feb 26, before the open (in 108 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $290.8M, 28% more than a year ago.
“Year-over-year growth in the third quarter of 2026 was driven by momentum from the gout expansion and continued progress in the existing specialty areas of Nephrology, Neurology, Rheumatology, Ophthalmology, and Pulmonology .”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Sales of Cortrophin Gel | $139M | $117M | $102M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| Adjusted non-GAAP gross margin | 60.3% to 61.0% |
“However, revenue conversion was slower than expected in both existing specialties and gout, due to capacity constraints in the Company’s specialty pharmacy network.”
From its results filing (SEC filing · Nov 5)
Sales grew 34% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 12% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +1.9% | -2.8% | not yet |
| Aug 7, 2026 | -6.7% | -5.3% | -9.5% |
| May 8, 2026 | +4.6% | -2.4% | -5.2% |
Sales grew every year from 2018 to 2025, to $883M. It turned a profit in 2025 after a loss in 2024.
RSI 48.9, MACD below signal, below both averages. Not scored.
One insider sold $243K across 1 filing in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ANIP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
“Consolidation among pharmaceutical companies has created opportunities by reducing the number of competitors.”
ANIP scores 9 today, which Breakaway calls Average. It is #55 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Down 3% on Nov 6 while the S&P 500 rose 0.3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ANIP scores 9 today, which Breakaway calls Average (6 to 10). That is #55 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ANIP's 9.
One insider sold $243K across 1 filing in the last 6 months. No open-market buys on record. The newest is Ori Gutwerg, SVP, Generics, who sold $243K on Aug 10.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.